Darolutamide
Overview
Darolutamide is a nonsteroidal androgen receptor inhibitor used in the treatment of prostate cancer. It works by binding to androgen receptors and blocking the activity of male hormones such as testosterone that stimulate the growth and survival of prostate cancer cells. Unlike some earlier androgen receptor inhibitors, darolutamide has a distinct molecular structure associated with limited penetration across the blood-brain barrier, which may reduce certain central nervous system adverse effects. The drug is administered orally and is typically used in combination with androgen deprivation therapy, with or without chemotherapy depending on disease stage and indication. Darolutamide plays an important role in the management of non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer, helping delay disease progression and improve survival outcomes in selected patients.
Background and Date of Approval
Darolutamide was developed as a next-generation androgen receptor inhibitor for advanced prostate cancer management. The United States Food and Drug Administration initially approved darolutamide on July 30, 2019 for non-metastatic castration-resistant prostate cancer based on the ARAMIS clinical trial demonstrating improved metastasis-free survival. On August 5, 2022, the United States Food and Drug Administration approved darolutamide in combination with docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer following results from the Phase III ARASENS trial. More recently, on June 3, 2025, the United States Food and Drug Administration approved darolutamide with androgen deprivation therapy for metastatic castration-sensitive prostate cancer without mandatory chemotherapy, based on findings from the Phase III ARANOTE trial. Regulatory approvals have also been granted in multiple international markets including the European Union and Japan.
Uses
Darolutamide is indicated for the treatment of non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive or castration-sensitive prostate cancer. It is used in combination with androgen deprivation therapy and, in selected cases, with docetaxel chemotherapy. The therapy is intended to delay disease progression, reduce metastatic spread, and improve overall survival in patients with advanced prostate cancer.
Administration
Darolutamide is administered orally, typically at a dose of 600 mg twice daily taken with food. Treatment is usually continued alongside androgen deprivation therapy and may be combined with docetaxel in selected treatment regimens. Dose modifications may be required based on tolerability, renal impairment, hepatic impairment, or adverse reactions. Regular clinical and laboratory monitoring is recommended during therapy.
Side Effects
Common side effects include fatigue, rash, pain in the extremities, decreased appetite, constipation, hypertension, and weight gain. Laboratory abnormalities such as anemia and elevated liver enzymes may also occur. Most adverse effects are manageable with supportive care and dose adjustments when necessary.
Warnings
Serious adverse events include ischemic heart disease, severe hypertension, seizures, and liver function abnormalities. Although darolutamide has relatively lower central nervous system penetration compared to some related therapies, neurological adverse effects may still occur rarely. Embryo-fetal toxicity is a significant risk, and exposure during pregnancy may cause fetal harm. Severe hypersensitivity reactions and cardiovascular complications require prompt medical attention.
Precautions
Patients should undergo baseline cardiovascular evaluation, liver function assessment, and renal function testing before initiating therapy. Caution is required in patients with a history of seizures or significant cardiovascular disease. Darolutamide may interact with medications metabolized through transporter pathways including BCRP and OATP substrates. Concomitant use with certain statins and strong enzyme inducers may require monitoring or adjustment. Ongoing assessment of blood pressure and laboratory parameters is recommended during treatment.
Expert Tips
Darolutamide is particularly valuable for patients requiring androgen receptor inhibition with potentially lower risk of central nervous system toxicity. Early initiation in eligible patients may help delay metastatic progression and improve long-term outcomes. Clinicians should monitor cardiovascular health and liver function throughout therapy. Patient counselling should emphasize adherence to twice-daily dosing with food and reporting of neurological or cardiac symptoms. Coordination with oncology specialists and supportive care teams is important for optimizing treatment outcomes in advanced prostate cancer.